ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
German Bayer AG opens first Co.Lab life science incubator in Cambridge/Boston. This comprises state-of-the-art laboratories and collaborative workspaces specifically designed to support entrepreneurs focused on developing cell and gene therapies.
Transmembrane proteins play a variety of roles in physiological processes such as protein ligation, recognition, transport, anchoring, and transduction.
An anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway.
The BioRN Life Science cluster Rhine-Neckar has set the right course to further accelerate the start-up dynamic. Several lighthouse projects have been established recently, fostering innovation and providing the ideal breeding ground for biotech projects. Joint forces now develop strategies to attract investors and increase the visibility of the start-up community. The Life Science Investors´ Day Heidelberg has established itself as a top-class platform.
2. BIOTECH CIRCLE – Almost twice as many visitors as at last years premiere were welcomed by Biotech Austrias Chairman Peter Llewellyn-Davies in the Vienna Stock Exchange in April. Framed by a Flying Breakfast, the topic was the provocative question Science always wins?!
A new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology.
Carbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions.
Roche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
uniQure N.V. is to sell a portion of its royalty rights from the net sales o its hemophilia B gene therapy etranacogene dezaparvovec-drbl to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400m in cash. This financing provides uniQure with immediate, non-equity-dilutive capital to continue to invest in our AAV gene therapy pipeline and platform and to advance potentially breakthrough gene therapies for patients, including AMT-130 in Huntingtons disease, AMT-260 for refractory temporal lobe epilepsy, AMT-162 for SOD-1 ALS and other product candidates, statedMatt Kapusta, CEO of uniQure.
Etranacogene dezaparvovec-drbl is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a persons own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.
Under the terms of the agreement, uniQure will receive an upfront cash payment of $375m in exchange for the lowest royalty tier on CSL Behrings worldwide net sales of etranacogene dezaparvovec-drbl up to 1.85 times the purchase price until June 30, 2032 or, if such cap is not met by June 30, 2032, up to 2.25x the purchase price through December 31, 2038.
Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.